Cancer Cell Radiobiological Studies Using In-House-Developed α-Particle Irradiator.
(2015) In Cancer Biotherapy & Radiopharmaceuticals 30(9). p.386-394- Abstract
- An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10... (More)
- An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10 Gy. Radiation sensitivity was estimated using a tetrazolium salt-based colorimetric assay with absorbance measurements at 450 nm. The relative biological effectiveness for α-particles relative to γ-irradiation at 37% cell survival for the LNCaP, DU145, PC3, Capan-1, Panc-1, and BxPC-3 cells was 7.9 ± 1.7, 8.0 ± 0.8, 7.0 ± 1.1, 12.5 ± 1.6, 9.4 ± 0.9, and 6.2 ± 0.7, respectively. The results show the feasibility of constructing a desktop α-particle irradiator as well as indicate that both prostate and pancreatic cancers are good candidates for further studies of α-particle radioimmunotherapy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8235921
- author
- Nilsson, Jenny ; Bauden, Monika LU ; Nilsson, Jonas LU ; Strand, Sven-Erik LU and Elgqvist, Jörgen LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Biotherapy & Radiopharmaceuticals
- volume
- 30
- issue
- 9
- pages
- 386 - 394
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- pmid:26560194
- wos:000364485500003
- scopus:84946908215
- pmid:26560194
- ISSN
- 1557-8852
- DOI
- 10.1089/cbr.2015.1895
- project
- Pancreatic cancer
- language
- English
- LU publication?
- yes
- id
- dcaff552-c71b-472b-bbc6-675387f332a6 (old id 8235921)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26560194?dopt=Abstract
- date added to LUP
- 2016-04-01 10:06:38
- date last changed
- 2022-02-02 06:28:34
@article{dcaff552-c71b-472b-bbc6-675387f332a6, abstract = {{An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10 Gy. Radiation sensitivity was estimated using a tetrazolium salt-based colorimetric assay with absorbance measurements at 450 nm. The relative biological effectiveness for α-particles relative to γ-irradiation at 37% cell survival for the LNCaP, DU145, PC3, Capan-1, Panc-1, and BxPC-3 cells was 7.9 ± 1.7, 8.0 ± 0.8, 7.0 ± 1.1, 12.5 ± 1.6, 9.4 ± 0.9, and 6.2 ± 0.7, respectively. The results show the feasibility of constructing a desktop α-particle irradiator as well as indicate that both prostate and pancreatic cancers are good candidates for further studies of α-particle radioimmunotherapy.}}, author = {{Nilsson, Jenny and Bauden, Monika and Nilsson, Jonas and Strand, Sven-Erik and Elgqvist, Jörgen}}, issn = {{1557-8852}}, language = {{eng}}, number = {{9}}, pages = {{386--394}}, publisher = {{Mary Ann Liebert, Inc.}}, series = {{Cancer Biotherapy & Radiopharmaceuticals}}, title = {{Cancer Cell Radiobiological Studies Using In-House-Developed α-Particle Irradiator.}}, url = {{https://lup.lub.lu.se/search/files/1570615/8864967.pdf}}, doi = {{10.1089/cbr.2015.1895}}, volume = {{30}}, year = {{2015}}, }